Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

By Ott Brian   Blake Lesley   Kagan Ethel   Resnick Malca  

Journal of Neurology, Vol. 254, Iss. 3, 2007-03 ,pp. : 351-358

Springer Publishing Company

Access to resources Recommend Favorite

The cognitive management of daily life activities in patients with mild to moderate Alzheimer's disease in a day care centre: A case report

By Adam Stéphane   Van Der Linden Martial   Juillerat Anne-Claude   Salmon Eric  

Neuropsychological Rehabilitation, Vol. 10, Iss. 5, 2000-10 ,pp. : 485-509

Routledge Ltd

Access to resources Recommend Favorite

The prediction of response to Galantamine treatment in Patients with mild to moderate Alzheimer’s Disease

By  

Current Alzheimer Research, Vol. 11, Iss. 2, 2014-02 ,pp. : 110-118

Bentham Science Publishers

Access to resources Recommend Favorite

Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study

By  

Current Alzheimer Research, Vol. 15, Iss. 13, 2018-12 ,pp. : 1231-1243

Bentham Science Publishers

Access to resources Recommend Favorite

Practice Effects on Motor Control in Healthy Seniors and Patients with Mild Cognitive Impairment and Alzheimer's Disease

By Yan Jin   Dick Malcolm  

Aging, Neuropsychology, and Cognition (Neuropsychology, Development and Cogniti, Vol. 13, Iss. 3-4, 2006-12 ,pp. : 385-410

Routledge Ltd

Access to resources Recommend Favorite